Recent public news coverage is primarily focused on commodity prices and unrelated market events, with no direct news related to BetterLife Pharma’s business or developments.

• Sugar prices have continued to rise due to concerns about a weak monsoon in India [N1].
• Cotton prices showed gains in early trading [N3].
• Oil prices increased following reports that Iran halted US-Iran ceasefire negotiations [N5].
• Cocoa prices declined due to abundant supplies [N6].
• Coffee prices fell as Brazil’s coffee harvest is expected to resume [N7].
• Corn prices declined despite crude oil strength [N8].

BetterLife Pharma’s development of BETR-001 as a non-hallucinogenic LSD derivative addresses significant unmet needs in neuropsychiatric disorders, potentially offering a novel therapeutic option. The company’s proprietary recombinant interferon-alpha 2b for topical and inhaled formulations targets HPV-related cervical lesions and respiratory viral infections, including COVID-19, which could diversify its product portfolio. The management team’s experience and strategic use of contract manufacturing may support efficient development and commercialization.

BetterLife Pharma faces risks typical of early-stage biopharmaceutical companies, including clinical and regulatory uncertainties, capital constraints, and competition. The company has a working capital deficiency and has reported net losses, indicating ongoing funding needs. The timing and success of clinical trials for BETR-001, MM-001, and MM-003 remain uncertain. Market acceptance and reimbursement for novel therapies are also potential challenges. Intellectual property protection and manufacturing scale-up risks exist as well.

BetterLife Pharma’s moat is based on its proprietary drug candidates, including BETR-001 with a patented manufacturing process that avoids controlled substance restrictions, and its development of proprietary recombinant interferon-alpha 2b for its MM-001 and MM-003 products. The company’s approach to leveraging contract manufacturing and its intellectual property protections contribute to its competitive positioning. However, as a clinical-stage biopharmaceutical company, it faces typical industry risks including regulatory approval, clinical trial success, and capital requirements.

• Clinical and Regulatory Risk: The company’s product candidates are in preclinical or early clinical stages, with inherent risks of failure to demonstrate safety and efficacy or to obtain regulatory approvals.
• Financial Risk: BetterLife Pharma has a working capital deficiency and a history of net losses, indicating reliance on external financing to fund operations and development activities.
• Manufacturing and Supply Risk: The company relies on contract manufacturers for production, which must comply with GMP and safeguard intellectual property; disruptions or non-compliance could impact development and commercialization.
• Market Acceptance Risk: Even if approved, the company’s products may face challenges in market adoption, reimbursement, and competition from existing therapies.
• Intellectual Property Risk: Protection of proprietary technologies and manufacturing processes is critical; failure to protect or enforce IP rights could harm competitive position.

• BetterLife Pharma Inc. is a publicly traded biopharmaceutical company incorporated in British Columbia, Canada, with its registered office in Vancouver, BC [S1].
• The company develops patented pharmaceuticals, including BETR-001, a non-hallucinogenic second-generation LSD derivative targeting neuropsychiatric and neurological disorders such as major depressive disorder, anxiety disorder, and neuropathic pain [S1].
• BETR-001's active ingredient is 2-bromo-lysergic acid diethylamide (2-bromo-LSD), which mimics LSD's therapeutic potential without hallucinogenic effects; it is orally administered and intended as a self-administered medication prescribed by psychiatrists [S1].
• BETR-001 is at the preclinical development stage, with GMP manufacturing of oral capsules underway and plans for IND enabling toxicology studies and Phase 1A and 1B clinical trials [S1].
• The company’s subsidiary MedMelior Inc. has two pipeline products: MM-001, a topical cream formulation of interferon-alpha 2b (IFNa2b) for HPV-induced cervical intraepithelial neoplasia, and MM-003, a patent-pending proprietary IFNa2b inhalation formulation for respiratory viral infections including COVID-19 [S1].
• MM-001 has completed small Phase 1-2 trials using externally sourced IFNa2b; the company is developing its own recombinant IFNa2b for future trials and plans to file a new IND for Phase 2b studies in the US [S1].
• MM-003 is at the preclinical stage with ongoing manufacturing and formulation work; a pre-IND discussion with the FDA has occurred, and inhalation toxicology studies are planned; development timing is under reassessment due to COVID-19 vaccine advent [S1].
• The company uses contract development and manufacturing organizations on a fee-for-service basis for research, development, and production, engaging only GMP-compliant manufacturers with strong intellectual property safeguards [S1].
• BetterLife Pharma operates through subsidiaries including MedMelior Inc. (Canada), Blife Therapeutics Inc. (Canada), Altum Pharma (Australia) Pty Ltd., and Altum Pharmaceuticals (HK) Limited [S1].
• The management team includes Chairman Doug Drysdale (appointed 2026), CEO Ahmad Doroudian (since 2020), CFO Moira Ong (since 2010), COO Hooshmand Sheshbaradaran (since 2020), and directors Ralph Anthony Pullen and Steven Sangha [S1].
• Financial snapshot as of October 31, 2018 (Q3 2019 fiscal year) shows cash and equivalents of $406,901 USD, current assets of $556,024 USD, and current liabilities of $3,650,935 USD, resulting in a current ratio of 0.15 and cash ratio of 0.11 [report_input.sec_financial_snapshot].
• The company reported net losses in prior years, with a net loss of $1,512,918 for the year ended January 31, 2026, and has an accumulated deficit of approximately $120 million as of January 31, 2026 [S1].
• BetterLife Pharma’s common shares are quoted on the Canadian Securities Exchange (symbol BETR) and OTCQB (symbol BETRF) [S1].
• As of May 29, 2026, the company had 161,787,025 common shares issued and outstanding [S1].
• Major shareholders include CEO Ahmad Doroudian (10.92%) and director Steven Sangha (15.52%) [S1].
• The company has a working capital deficiency, with current liabilities significantly exceeding current assets as of January 31, 2026 [S1].
• The company has disclosed risks including the need to raise additional funds to support ongoing operations and uncertainties related to product development and commercialization [S1].